DK1146885T3 - Forbehandling mod celledød - Google Patents

Forbehandling mod celledød

Info

Publication number
DK1146885T3
DK1146885T3 DK00900465T DK00900465T DK1146885T3 DK 1146885 T3 DK1146885 T3 DK 1146885T3 DK 00900465 T DK00900465 T DK 00900465T DK 00900465 T DK00900465 T DK 00900465T DK 1146885 T3 DK1146885 T3 DK 1146885T3
Authority
DK
Denmark
Prior art keywords
disorders
apoptosis
aliquot
exposure
conditioning
Prior art date
Application number
DK00900465T
Other languages
English (en)
Inventor
Mandel Arkady
E Bolton Anthony
Pavel Hamet
Johanne Tremblay
Christine Desrosier
Huifang Cheng
Original Assignee
Ct De Rech Du Ct Hospitalier D
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Rech Du Ct Hospitalier D, Vasogen Ireland Ltd filed Critical Ct De Rech Du Ct Hospitalier D
Application granted granted Critical
Publication of DK1146885T3 publication Critical patent/DK1146885T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/369—Temperature treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0216—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
    • A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00900465T 1999-01-12 2000-01-11 Forbehandling mod celledød DK1146885T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11563699P 1999-01-12 1999-01-12
PCT/CA2000/000029 WO2000041705A1 (en) 1999-01-12 2000-01-11 Pre-conditioning against cell death

Publications (1)

Publication Number Publication Date
DK1146885T3 true DK1146885T3 (da) 2003-09-22

Family

ID=22362576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00900465T DK1146885T3 (da) 1999-01-12 2000-01-11 Forbehandling mod celledød

Country Status (14)

Country Link
EP (1) EP1146885B1 (da)
JP (1) JP2002534473A (da)
AT (1) ATE241370T1 (da)
AU (1) AU771162B2 (da)
CA (1) CA2360268A1 (da)
DE (1) DE60002979T2 (da)
DK (1) DK1146885T3 (da)
ES (1) ES2202034T3 (da)
HK (1) HK1043726B (da)
IL (2) IL144242A0 (da)
MX (1) MXPA01007111A (da)
NZ (1) NZ512849A (da)
PT (1) PT1146885E (da)
WO (1) WO2000041705A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2324199A1 (en) * 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
CA2327630A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Transforming growth factor regulation
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
IL148924A (en) * 2002-03-26 2015-06-30 Mor Research Applic Ltd Use of substances that inhibit intracellular elastase activity in the preparation of a drug for the treatment and / or prevention of necrosis of cells and related diseases
EP1773360A4 (en) * 2004-07-20 2009-09-02 Vasogen Ireland Ltd TREATMENT OF ACUTE INFLAMMATORY EVENTS
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
NZ249176A (en) * 1992-02-07 1996-11-26 Vasogen Inc Method of increasing concentration of nitric oxide in blood using ozone and uv radiation
AU3506293A (en) * 1992-02-07 1993-09-03 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
AU721530B2 (en) * 1995-05-05 2000-07-06 Vasogen Ireland Limited Endothelial lining effects and treatment of vasospastic disorders
CA2191940A1 (en) * 1996-12-03 1998-06-03 Johannes Lohnert Surgical wound healing acceleration
AU741181B2 (en) * 1997-09-12 2001-11-22 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal Treatment of stress and preconditioning against stress

Also Published As

Publication number Publication date
PT1146885E (pt) 2003-10-31
HK1043726A1 (en) 2002-09-27
WO2000041705A1 (en) 2000-07-20
IL144242A0 (en) 2002-05-23
CA2360268A1 (en) 2000-07-20
JP2002534473A (ja) 2002-10-15
AU771162B2 (en) 2004-03-18
HK1043726B (zh) 2004-10-15
EP1146885B1 (en) 2003-05-28
DE60002979D1 (de) 2003-07-03
EP1146885A1 (en) 2001-10-24
NZ512849A (en) 2003-02-28
ATE241370T1 (de) 2003-06-15
IL144242A (en) 2007-07-04
ES2202034T3 (es) 2004-04-01
DE60002979T2 (de) 2004-05-19
MXPA01007111A (es) 2002-03-27
AU3028000A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
Lapeš et al. Photodynamic therapy of cutaneous metastases of breast cancer after local application of meso-tetra-(para-sulphophenyl)-porphin (TPPS4)
ATE378014T1 (de) System zum behandeln von abnormalem gewebe in der menschlichen speiseröhre
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
DE60107065D1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
Neganova et al. Mechanisms of antioxidant effect of natural sesquiterpene lactone and alkaloid derivatives
DK1146885T3 (da) Forbehandling mod celledød
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ZA200004260B (en) Treatment of skin disorders.
WO2009117828A8 (en) Saponin extract from saponaria spp. and uses thereof
EA200500849A1 (ru) Новые соединения лапахона и способы их применения
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
Debnath et al. Antioxidant potential and oxidative DNA damage preventive activity of Chrysanthemum indicum extracts
Lubart et al. Biostimulative effects of low‐energy lasers and their implications for medicine
WO2003004091A3 (en) Aromatic sulfenates for type i phototherapy
ES2185323T3 (es) Utilizacion de eritropoietina en el tratamiento del mieloma multiple.
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
CN106317170B (zh) 一种紫苏籽抗氧化肽及其应用
DE69629436D1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
Woo et al. Quercetin prevents necrotic cell death induced by co-exposure to benzo (a) pyrene and UVA radiation
CN106478770B (zh) 一种紫苏籽抗氧化二肽及其制备方法与应用